Targeted therapies in Pulmonary arterial Hypertension (PAH)

Phosphodiesterase Type 5 Inhibitors Sildenafil-Decrease concentration of sildenafil and N-desmethyl-sildenafil-Dose adjustment of sildenafil may be necessary based upon clinical response. Vardenafil-No recommendations provided in PI. Tadalafil-No recommendations provided in PI Table 7. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download